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In Belarus and other Slavic countries, founder mutations
in the BRCA1 gene are responsible for a significant pro-
portion of breast cancer cases. BRCA1 mutations also
predispose to ovarian cancer. The aim of this study was
to estimate the frequency of the three BRCA1 founder
mutations in Belarus. The study group consisted of 134
consecutive, newly diagnosed cases of ovarian cancer
after surgical treatment, unselected for age or family his-
tory. The control group constituted 853 blood samples
from newborn children (417 girls and 436 boys). All
patients were inhabitants of the western region of
Belarus. DNA was extracted from peripheral blood lym-
phocytes for cases and from cord blood from afterbirth.
Two BRCA1 mutations (4153delA and 5382insC) were
studied using ASA-PCR and one mutation (C61G) was
detected with RFLP-PCR. A mutation was identified in 9
of 853 newborn controls (1.1%). The 5382insC mutation
was the most common (78%). A BRCA1 mutation was
detected in 18 of the 134 (13.4%) unselected ovarian
cancer cases. The median age of diagnosis of the 18 her-
editary ovarian cancers was 54±10 years. (range 41–79
years). The frequency of a BRCA1 mutation in underly-
ing population and hereditary proportion of ovarian
cancer in Belarus is among the highest of any countries
studied to date.
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